Browse: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 3 |
Amgen Inc. patentsThe following is a sampling of recent Amgen Inc. patent applications (USPTO Patent Application #, Patent Title) sorted by month.
August 2012 - Amgen Inc. patents
20120216878 - Valve for controlling the flow of steam and other fluids 20120220583 - Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use 20120220585 - Heterocyclic compounds and their uses 20120220586 - Heterocyclic compounds and their uses 20120213779 - Fgf21 mutants and uses thereof 20120213797 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) 20120214204 - Cell culture media for uvc exposure and methods related thereto 20120208760 - Thrombopoietic compounds 20120195879 - Carrier immunoglobulins and uses thereof 20120195985 - Glycine transporter-1 inhibitors July 2012 - Amgen Inc. patents
20120190666 - Heteroaryl compounds as pikk inhibitors 20120190829 - Antigen binding proteins capable of binding thymic stromal lymphopoietin 20120183546 - Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane 20120183561 - Alpha-4-beta-7 heterodimer specific antagonist antibody 20120177646 - Fgf21 mutants and uses thereof 20120177662 - Alpha-4-beta-7 heterodimer specific antagonist antibody 20120178685 - Fgf21 mutants and uses thereof June 2012 - Amgen Inc. patents
20120165334 - Indole/benzimidazole compounds as mtor kinase inhibitors 20120156725 - Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors 20120148531 - Fused heterocyclic derivatives and methods of use 20120142605 - Methods of treating psoriasis May 2012 - Amgen Inc. patents
20120136163 - method for the preparation of 1-acetyl-6-amino-3,3-dimethyl-2,3-dihydroindole 20120129771 - Peptides and related molecules that modulate nerve growth factor activity 20120121591 - Selective and potent peptide inhibitors of kv1.3 20120122847 - Aurora kinase modulators and method of use 20120115811 - Phenylanaline amide derivatives useful for treating insulin-related diseases and conditions 20120116057 - Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering 20120107275 - Fused heterocyclic derivatives and methods of use 20120108587 - Aza- and diaza-phthalazine compounds as p38 map kinase modulators and methods of use thereof April 2012 - Amgen Inc. patents
20120088749 - S1p receptor modulating compounds and use thereof March 2012 - Amgen Inc. patents
20120070432 - Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine 20120071474 - Inhibitors of pi3 kinase 20120065185 - Substituted alkylamine derivatives and methods of use February 2012 - Amgen Inc. patents
20120039880 - Fragmentation resistant igg1 fc-conjugates 20120040983 - Phthalazine compounds as p38 map kinase modulators and methods of use thereof 20120034237 - Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof 20120034657 - Thrombopoietic compounds 20120027765 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) 20120028877 - Self-buffering protein formulations 20120028917 - Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistant cancer January 2012 - Amgen Inc. patents
20120020918 - Il-1 family variants 20120020976 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) 20120020975 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) 20120021459 - Feed media 20120009190 - Identification and method for using the pre-ligand assembly domain of the il-17 receptor 20120010256 - Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 20120010594 - Drug delivery device 20120003216 - Fgf21 mutants and uses thereof 20120003237 - Wise binding agents and epitopes August 2011 - Amgen Inc. patents
20110201602 - Protein kinase modulators and method of use 20110195895 - Fgf21 mutants and uses thereof 20110190330 - Spirocyclic gpr40 modulators July 2011 - Amgen Inc. patents
20110166331 - Il-17 receptor a antigen binding proteins June 2011 - Amgen Inc. patents
20110151579 - Secreted epithelial stromal-1 molecules and uses thereof May 2011 - Amgen Inc. patents
20110117053 - Method of modulating fibroblast accumulation or collagen deposition 20110118250 - Beta-secretase modulators and methods of use 20110118252 - Substituted amide derivatives and methods of use 20110104757 - Human anti-b7rp1 neutralizing antibodies 20110105499 - Pyrazolo-pyrazinone compounds and methods of use thereof 20110105498 - Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators and methods of use thereof April 2011 - Amgen Inc. patents
20110097305 - Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors 20110097318 - Solid-state protein formulation 20110097336 - Methods for modulating mannose content of recombinant proteins 20110092504 - Inhibitors of pi3 kinase 20110086834 - Alkynyl alcohols as kinase inhibitors 20110081339 - Methods of using il-17 receptor a antibodies March 2011 - Amgen Inc. patents
20110052604 - Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors February 2011 - Amgen Inc. patents
20110044986 - Anti-amyloid antibodies and uses thereof 20110045587 - Toxin peptide therapeutic agents 20110033472 - Tumor endothelial marker 5-alpha molecules and uses thereof 20110034487 - Cxcr3 antagonists
###
This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Amgen Inc. in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Amgen Inc. with additional patents listed. Browse our Agent directory for other possible listings.
###
FreshPatents.com Support - Terms & Conditions
|